Verition Fund Management
APGE

Verition Fund Management’s Apogee Therapeutics APGE Stock Holding History

Verition Fund Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265K Buy
+2,000
New +$180K ﹤0.01% 1781

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Verition Fund Management's APGE Position: Q2 2026 in Review

Verition Fund Management opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 159,256 shares worth $21.1M. The stake represents 0.11% of the portfolio and ranks #197 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in APGE as recently as Q4 2025.

Verition Fund Management first reported a position in APGE in Q4 2024 and has held it in 4 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Verition Fund Management held 159,256 shares of Apogee Therapeutics worth $21.1M as of Q2 2026.
  • Apogee Therapeutics was a new Verition Fund Management position in Q2 2026.
  • Apogee Therapeutics made up 0.11% of Verition Fund Management's portfolio in Q2 2026, its #197 holding.
  • Verition Fund Management first reported a position in Apogee Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.